Vidac Pharma Launches“TME++” Pediatric Brain Tumor Research Consortium

Brain Tumor research consortium for pediatric brain cancer Vidac Pharma has announced the formation of“TME++,” a groundbreaking research consortium dedicated to advancing treatments for pediatric brain tumors. Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) Max Herzberg Vidac pharma Holding Plc +972 54-425-7381 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liabilityfor the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in thisarticle.

If you have any complaints or copyright issues related to this article, kindly contact the author above. MENAFN24032025003118003196ID1109347940 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article.



If you have any complaints or copyright issues related to this article, kindly contact the provider above..